OPKO Health (OPK) Stock Price, News & Analysis

Company Overview

OPKO Health, Inc. (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States. BioReference offers routine clinical testing, women’s health panels, oncology diagnostics, genetic and genomic assays, and esoteric testing to hospitals, physicians and clinical research organizations. During the COVID-19 pandemic, the laboratory network expanded testing capacity to meet growing public health needs. Beyond the U.S., OPKO’s diagnostic operations extend into Latin America, serving customers in Mexico, Brazil and Argentina.

OPKO’s Pharma Services & Products segment is dedicated to the development, licensing and commercialization of innovative therapeutics. The company’s marketed portfolio includes Rayaldee®, an FDA-approved treatment for secondary hyperparathyroidism in adults with stage 3–4 chronic kidney disease. OPKO also advances a pipeline of small molecules, biosimilars and novel biologics targeting metabolic disorders, endocrinology and oncology. Strategic collaborations and in-licensing arrangements bolster the company’s research capabilities and expand its product offerings.

Founded in 2007, OPKO has grown through strategic acquisitions—most notably the 2015 purchase of BioReference Laboratories—and partnerships with academic and industry leaders. Under the leadership of Chairman and CEO Dr. Phillip Frost, a physician-scientist and experienced biotech entrepreneur, the company emphasizes an integrated approach that combines advanced diagnostics with precision therapeutics. OPKO continues to pursue geographic expansion and pipeline diversification to meet evolving healthcare demands worldwide.

Key Stats

• Today's Range: $1.20 to $1.26
• 50-Day Range: $1.10 to $1.53
• 52-Week Range: $0.98 to $1.61
• Volume: 1.06 million shs
• Average Volume: 2.75 million shs
• Market Capitalization: $917.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.55
• Consensus Rating: Reduce

OPKO Health Stock Analysis - MarketRank™

OPKO Health scored higher than 42% of companies evaluated by MarketBeat, and ranked 636th out of 853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

OPKO Health has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

OPKO Health has a consensus price target of $1.55, representing about 27.6% upside from its current price of $1.22.

Amount of Analyst Coverage

OPKO Health has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for OPKO Health are expected to remain at ($0.29) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of OPKO Health is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OPKO Health is -4.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OPKO Health has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.81% of the float of OPKO Health has been sold short.

Short Interest Ratio / Days to Cover

OPKO Health has a short interest ratio ("days to cover") of 8.93.

Change versus previous month

Short interest in OPKO Health has recently decreased by 0.59%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OPKO Health does not currently pay a dividend.

Dividend Growth

OPKO Health does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.03

News Sentiment

OPKO Health has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for OPKO Health this week, compared to 3 articles on an average week.

Search Interest

Only 17 people have searched for OPK on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

MarketBeat Follows

4 people have added OPKO Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OPKO Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

44.72% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.63% of the stock of OPKO Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 4/28/2026
• Today: 7/15/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OPK
• CIK: 944809
• Web: www.opko.com
• Phone: (305) 575-4100
• Fax: 305-575-6015
• Employees: 1,373
• Year Founded: 2007

Price Target and Rating

• Average Price Target for OPKO Health: $1.55
• High Price Target: $1.60
• Low Price Target: $1.50
• Potential Upside/Downside: +26.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$225.68 million
• Net Margins: -36.63%
• Pretax Margin: -39.39%
• Return on Equity: -16.78%
• Return on Assets: -10.98%

Debt

• Debt-to-Equity Ratio: 0.28
• Current Ratio: 3.61
• Quick Ratio: 3.17

Sales & Book Value

• Annual Sales: $581.12 million
• Price / Sales: 1.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 0.73

Miscellaneous

• Outstanding Shares: 755,092,000
• Free Float: 417,415,000
• Market Cap: $924.99 million
• Optionable: Optionable
• Beta: 1.48